Abstract
Negative and cognitive symptoms of schizophrenia remain difficult to treat. Many add-on medications to alleviate these symptoms have been proposed and investigated. In this inventory the various treatment strategies published since 1990 are being reviewed and categorised according to the pharmacological mechanism putatively involved. Notwithstanding the problems one experiences when comparing the applied measures for negative and cognitive symptoms, three clear recommendations for future research can be made viz. modulation of glutamatergic systems, blockade of serotonin 5-HT2 receptors and modulation of histaminergic systems. Strategies aimed at nAChR subtypes may also hold some promise.
Keywords: Schizophrenia, negative symptoms, cognitive dysfunction, add-on medication
Central Nervous System Agents in Medicinal Chemistry
Title: Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research
Volume: 8 Issue: 1
Author(s): Gerben Duisterwinkel, F. J. Bosker, A. N. Scholte-Stalenhoef, M. Vervoort and H. Knegtering
Affiliation:
Keywords: Schizophrenia, negative symptoms, cognitive dysfunction, add-on medication
Abstract: Negative and cognitive symptoms of schizophrenia remain difficult to treat. Many add-on medications to alleviate these symptoms have been proposed and investigated. In this inventory the various treatment strategies published since 1990 are being reviewed and categorised according to the pharmacological mechanism putatively involved. Notwithstanding the problems one experiences when comparing the applied measures for negative and cognitive symptoms, three clear recommendations for future research can be made viz. modulation of glutamatergic systems, blockade of serotonin 5-HT2 receptors and modulation of histaminergic systems. Strategies aimed at nAChR subtypes may also hold some promise.
Export Options
About this article
Cite this article as:
Duisterwinkel Gerben, Bosker J. F., Scholte-Stalenhoef N. A., Vervoort M. and Knegtering H., Antipsychotic Augmentation Strategies to Ameliorate Negative and Cognitive Symptoms in Schizophrenia; Implications for Future Research, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (1) . https://dx.doi.org/10.2174/187152408783790631
DOI https://dx.doi.org/10.2174/187152408783790631 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Achievements on Siderophore Production and Application
Recent Patents on Biotechnology Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Endothelin-Converting Enzyme Inhibitors
Current Enzyme Inhibition Subject Index to Volume 10
Current Medicinal Chemistry Biologics for ANCA-Associated Vasculitis
Inflammation & Allergy - Drug Targets (Discontinued) When and How Should We Cover Patients for Community-Acquired Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia?
Current Respiratory Medicine Reviews Adrenomedullin in Cardiovascular Disease: A Useful Biomarker, its Pathological Roles and Therapeutic Application
Current Protein & Peptide Science Joshanda: A Traditional Herbal Approach for Treatment of Respiratory Catarrh
Current Respiratory Medicine Reviews The Role of Immunosuppressive Medications in the Pathogenesis of Hypertension and Efficacy and Safety of Antihypertensive Agents in Kidney Transplant Recipients
Current Medicinal Chemistry Male Pelvic Pain: Beyond Urology and Chronic Prostatitis
Current Rheumatology Reviews Targeting the Endocannabinod System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury
Current Pharmaceutical Biotechnology History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design An Overview of Non-Neural Sources of Calcitonin Gene-Related Peptide
Current Medicinal Chemistry Synthesis, Characterization, Biological Activity of Novel 1H-benzo[f]- chromene and 12H-benzo[f]chromeno[2,3-d]pyrimidine Derivatives
Letters in Drug Design & Discovery Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry Improving Adherence to Antipsychotic Pharmacotherapy
Current Clinical Pharmacology Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Urocortin: Cardiovascular Actions and Therapeutic Implications
Letters in Drug Design & Discovery